Polymyalgia Rheumatica Market Report 2026

The polymyalgia rheumatica market size has grown strongly in recent years. It will grow from $1.36 billion in 2025 to $1.44 billion in 2026 at a compound annual growth rate (CAGR) of 6.2%. The growth in the historic period can be attributed to increasing aging population size, improved clinical awareness of inflammatory disorders, established use of corticosteroids as first-line therapy, growing diagnosis rates in geriatric patients, availability of hospital-based rheumatology services.

The polymyalgia rheumatica market size is expected to see strong growth in the next few years. It will grow to $1.81 billion in 2030 at a compound annual growth rate (CAGR) of 5.9%. The growth in the forecast period can be attributed to growing development of steroid-sparing therapies, rising research on inflammatory biomarkers, increasing adoption of biologics and targeted drugs, expanding access to specialized care, growing focus on reducing long-term treatment side effects. Major trends in the forecast period include increasing adoption of biologic therapies, rising focus on early and accurate diagnosis, growing use of long-term corticosteroid management, expansion of personalized treatment approaches, enhanced monitoring of disease progression.

The growing demand for personalized medicine is expected to drive the growth of the polymyalgia rheumatica market going forward. Personalized medicine refers to medical treatment that is tailored to an individual’s genetic profile, lifestyle, and specific health conditions to achieve more effective outcomes. The increasing demand for personalized medicine is supported by advancements in genetic research, rising patient expectations for customized therapies, and improvements in diagnostic technologies. Genetic research has enhanced understanding of individual genetic variations, enabling the development of targeted treatments that address specific genetic markers. Personalized medicine also helps clinicians select therapies that are more likely to be effective based on patient characteristics, resulting in safer and more efficient treatment approaches. For instance, in February 2024, according to the Personalized Medicine Coalition, a US-based healthcare organization, the Food and Drug Administration approved 16 new personalized treatments for rare disease patients in 2023, compared to six approvals in 2022. Therefore, the increasing adoption of personalized medicine is contributing to the growth of the polymyalgia rheumatica market.

The expansion of telemedicine services is expected to further support the growth of the polymyalgia rheumatica market. Telemedicine services use digital communication tools such as video calls, phone consultations, and online platforms to deliver remote medical care, including diagnosis, treatment, and follow-up, without requiring in-person visits. The growth of telemedicine is driven by rising demand for convenient and cost-effective healthcare solutions. Patients increasingly prefer remote consultations, particularly for non-urgent care, due to the convenience and accessibility offered by telemedicine. Telemedicine supports polymyalgia rheumatica management by enabling remote symptom monitoring, medication management, and regular follow-ups, which are essential for controlling chronic pain and inflammation. For instance, in November 2024, according to the Australian Bureau of Statistics, an Australia-based government agency, telehealth usage increased from 87.7% in 2022-23 to 89.2% in 2023-24. Therefore, the growth of telemedicine services is driving the expansion of the polymyalgia rheumatica market.

Major companies operating in the polymyalgia rheumatica market are focusing on developing advanced therapies, such as interleukin-6 receptor blockers, to offer more targeted and effective treatment options. Interleukin-6 receptor blockers are biologic drugs that inhibit IL-6, a key inflammatory cytokine involved in autoimmune conditions. By blocking IL-6 activity, these therapies help reduce inflammation and alleviate symptoms, improving patient quality of life. For instance, in February 2023, Regeneron Pharmaceuticals, Inc., a US-based biotechnology company, and Sanofi, a France-based healthcare company, announced that the Food and Drug Administration approved Kevzara (sarilumab) for the treatment of polymyalgia rheumatica in adults who do not respond adequately to corticosteroids or are unable to tolerate steroid tapering. Kevzara is the first biologic approved for this indication and works by inhibiting IL-6 signaling. The approval was supported by clinical data showing that 28.3% of patients treated with sarilumab achieved sustained remission at week 52, compared to 10.3% in the placebo group. Kevzara is administered as a subcutaneous injection every two weeks and is also approved for the treatment of moderately to severely active rheumatoid arthritis.

Major companies operating in the polymyalgia rheumatica market are AbbVie Inc., Sanofi S.A., Eli Lilly and Co., Regeneron Pharmaceuticals Inc., Horizon Therapeutics plc, Sparrow Pharmaceuticals Inc., Roche Holding AG, Novartis AG, Pfizer Inc., Bristol Myers Squibb Company, GlaxoSmithKline plc, AstraZeneca plc, Merck & Co. Inc., Janssen Pharmaceuticals Inc., Takeda Pharmaceutical Company Limited, UCB S.A., Amgen Inc., Boehringer Ingelheim, Bayer AG, Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Lupin Limited, Aurobindo Pharma Limited.

Asia-Pacific was the largest region in the polymyalgia rheumatica market in 2025. The regions covered in the polymyalgia rheumatica market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the polymyalgia rheumatica market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the polymyalgia rheumatica market by increasing costs of imported active pharmaceutical ingredients, biologics, and specialty drug manufacturing inputs used in corticosteroids and advanced immunotherapies. North America and Europe are most affected due to dependence on global pharmaceutical supply chains, while Asia-Pacific faces cost pressures related to bulk drug exports. These tariffs are contributing to higher treatment costs and reimbursement challenges. However, they are also encouraging local API manufacturing, regional drug production, and increased investments in domestic pharmaceutical supply resilience.

The polymyalgia rheumatica market research report is one of a series of new reports that provides polymyalgia rheumatica market statistics, including polymyalgia rheumatica industry global market size, regional shares, competitors with a polymyalgia rheumatica market share, detailed polymyalgia rheumatica market segments, market trends and opportunities, and any further data you may need to thrive in the polymyalgia rheumatica industry. This polymyalgia rheumatica market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Polymyalgia rheumatica is an inflammatory condition that mainly affects older adults and is characterized by muscle pain and stiffness, especially in the shoulders, hips, and neck. The condition causes aching and inflammation in the muscles surrounding these areas, which can lead to reduced mobility and difficulty performing daily activities.

The primary treatment options for polymyalgia rheumatica include corticosteroids, nonsteroidal anti-inflammatory drugs, disease-modifying antirheumatic drugs, and biologics. Corticosteroids are the mainstay of treatment for polymyalgia rheumatica, as they help reduce inflammation and relieve symptoms by mimicking natural adrenal hormones. These treatments are administered through various routes, including oral, intravenous, and subcutaneous methods, and are used for different patient groups such as adults, geriatric patients, and pediatric patients. They are distributed through hospital pharmacies, retail pharmacies, and online pharmacies.

The polymyalgia rheumatica market consists of revenues earned by entities by providing services such as medication management, pain management, laboratory testing, and nutritional counseling. The market value includes the value of related goods sold by the service provider or included within the service offering. The polymyalgia rheumatica market includes sales of disease-modifying anti-rheumatic drugs, calcium and vitamin D supplements, assistive devices, and physical therapy aids. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.